澳優(01717.HK)取得湖南省首張特殊醫學用途配方食品生產許可證
澳優(01717.HK)公佈,近日取得湖南省市場監管局頒發的全省首張特殊醫學用途配方食品生產許可證,涉及一款特殊醫學用途嬰兒無乳糖配方食品。
該產品已於2021年4月通過國家市場監督管理總局特醫食品註冊,產品類別爲無乳糖配方,其營養成分可滿足0至6月齡乳糖不耐受嬰兒的生長髮育需求。公司表示,按照計劃新產品將於今年4月正式上市,料將進一步拓寬澳優的生產業務範圍,延伸產品矩陣,提升核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.